ACAD Key Statistics, Chart & Performance
The current stock price of ACAD is 27.62 USD. In the past month the price increased by 11.33%. In the past year, price increased by 62.95%.
ACAD Latest News, Press Relases and Analysis
ACAD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.34 | 406.46B | ||
| AMGN | AMGEN INC | 15.22 | 179.28B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.66 | 117.45B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.47 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.94B | ||
| NTRA | NATERA INC | N/A | 32.26B | ||
| BIIB | BIOGEN INC | 10.58 | 25.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.22 | 21.84B | ||
| INCY | INCYTE CORP | 15.59 | 19.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About ACAD
Company Profile
ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. The company is headquartered in San Diego, California and currently employs 653 full-time employees. The company went IPO on 2004-05-27. The company develops and commercializes medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. The company has a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and ACP-711. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Its early-stage research programs and product candidates include ACP-211, ACP-2591, ACP-271, and Antisense Oligonucleotide (ASO) Programs.
Company Info
ACADIA PHARMACEUTICALS INC
12830 El Camino Real, Suite 400
San Diego CALIFORNIA 92130 US
CEO: Stephen R. Davis
Employees: 654
Phone: 18585582871
ACADIA PHARMACEUTICALS INC / ACAD FAQ
What does ACADIA PHARMACEUTICALS INC do?
ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. The company is headquartered in San Diego, California and currently employs 653 full-time employees. The company went IPO on 2004-05-27. The company develops and commercializes medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. The company has a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and ACP-711. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Its early-stage research programs and product candidates include ACP-211, ACP-2591, ACP-271, and Antisense Oligonucleotide (ASO) Programs.
Can you provide the latest stock price for ACADIA PHARMACEUTICALS INC?
The current stock price of ACAD is 27.62 USD. The price decreased by -0.9% in the last trading session.
What is the dividend status of ACADIA PHARMACEUTICALS INC?
ACAD does not pay a dividend.
How is the ChartMill rating for ACADIA PHARMACEUTICALS INC?
ACAD has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the analyst forecast for ACAD stock?
26 analysts have analysed ACAD and the average price target is 29.85 USD. This implies a price increase of 8.07% is expected in the next year compared to the current price of 27.62.
How is the valuation of ACADIA PHARMACEUTICALS INC (ACAD) based on its PE ratio?
The PE ratio for ACADIA PHARMACEUTICALS INC (ACAD) is 41.22. This is based on the reported non-GAAP earnings per share of 0.67 and the current share price of 27.62 USD.
What is the market capitalization of ACAD stock?
ACADIA PHARMACEUTICALS INC (ACAD) has a market capitalization of 4.67B USD. This makes ACAD a Mid Cap stock.
ACAD Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ACAD. When comparing the yearly performance of all stocks, ACAD is one of the better performing stocks in the market, outperforming 92.87% of all stocks.
ACAD Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to ACAD. ACAD is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
ACAD Financial Highlights
Over the last trailing twelve months ACAD reported a non-GAAP Earnings per Share(EPS) of 0.67. The EPS decreased by -14.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 24.94% | ||
| ROA | 19.63% | ||
| ROE | 28.47% | ||
| Debt/Equity | 0 |
ACAD Forecast & Estimates
26 analysts have analysed ACAD and the average price target is 29.85 USD. This implies a price increase of 8.07% is expected in the next year compared to the current price of 27.62.
For the next year, analysts expect an EPS growth of 73.59% and a revenue growth 11.07% for ACAD